Upadacitinib for Refractory Alopecia Areata Unresponsive to Prior Systemic Therapies: A Retrospective Study

Supplemental figure I showing the efficacy of Upadacitinib; Supplemental table Idetailing baseline SALT scores, changes in SALT scores, and serum IgE levels for each patient with refractory alopecia areata following treatment with Upadacitinib; Supplementary Table II. Correlation between characteristics of alopecia areata patients treated with upadacitinib and percentage of hair regrowth at week 24w.